Prescription skincare company Curology, formerly known as PocketDerm, has raised $15 million in a Series B financing round, the company announced Wednesday.

The $15-million round was led by Advance Vixeid Partners, a growth-equity investor that focuses on companies “at the intersection of the technology, media and marketing sectors.” Prior investors Sherpa Capital and Forerunner Ventures also participated.

Curology, a direct-to-consumer company that sells customized acne and anti-aging treatments, was co-founded by San Diego-based dermatologists Dr. David Lortscher and Dr. Nancy Satur in 2014.

"In the U.S., there is only one dermatologist for every 36,000 people – and most are concentrated in major metro areas, meaning access to specialists is limited,” Lortscher said. “As a result, many consumers settle for inadequate over-the-counter remedies.”

The company, which also has a San Francisco office, offers Internet-based dermatological consultations and personalized prescriptions for $20 per month.

Advance Vixeid principal Courtney Robinson said Curology is “fundamentally transforming the multibillion-dollar acne treatment market” by making treatments more accessible and affordable.